NCT01888835View on ClinicalTrials.gov

Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Amphetamine-Related Disorders
Interventions
DRUG

Mirtazapine

DRUG

Placebo

Trial Locations (1)

94102

Substance Use Research Unit, San Francisco

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Phillip Coffin, MD, MIA

OTHER_GOV

NCT01888835 - Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0) | Biotech Hunter | Biotech Hunter